Molecular pathology of malignant gliomas

Annual Review of Pathology

Volumn 1, Issue , 2006, Pages 97-117

  Louis, David N ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Astrocytoma; Genetics; Glioblastoma; Oligodendroglioma; Pathology

Indexed keywords

CATHEPSIN B; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; FOCAL ADHESION KINASE; GELATINASE A; GELATINASE B; LOMUSTINE; PLATELET DERIVED GROWTH FACTOR; PROCARBAZINE; TENASCIN; UROKINASE RECEPTOR; VINCRISTINE; VITRONECTIN;

ANGIOGENESIS; ASTROCYTOMA; BRAIN TUMOR; CANCER GRADING; CANCER GROWTH; CANCER STEM CELL; CELL DIFFERENTIATION; GLIOBLASTOMA; HYPOXIA; NECROSIS; NEURAL STEM CELL; OLIGODENDROGLIOMA; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

EID: 33645732219     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev.pathol.1.110304.100043     Document Type: Review

References (76)

1. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DM, et al. 2001. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 15:1311-33
2. Holland EC. 2001. Gliomagenesis: genetic alterations and mouse models. Nat. Rev. Genet. 2:120-29
3. Louis DN, Pomeroy SL, Cairncross JG. 2002. Focus on CNS neoplasia. Cancer Cell 1:125-28
4. Kleihues P, Cavenee WK. 2000. World Health Organization Classification of Tumours of the Nervous System. Lyon: WHO/IARC
5. Louis DN, Holland EC, Cairncross JG. 2001. Glioma classification: a molecular reappraisal. Am. J. Pathol. 159:779-86
6. Davis FG, Preston-Martin S. 1998. Epidemiology: incidence and survival. In Russell and Rubinstein's Pathology of Tumors of the Nervous System, ed. DD Bigner, RE McLendon, JM Bruner, pp. 5-45. London: Arnold
7. Russell DS, Rubinstein LJ. 1989. Pathology of Tumours of the Nervous System. Baltimore: Williams & Wilkins
8. Holland EC, Celestino J, Dai CK, Schaefer L, Sawaya RE, Fuller GN. 2000. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat. Genet. 25:55-57
9. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC. 2001. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev. 15:1913-25
10. Bachoo RM, Maher EA, Ligon KL, Sharpless NE, Chan SS, et al. 2002. Epidermal growth factor receptor and Ink4a/Arf: covergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1:269-77
11. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, et al. 2004. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64:7011-21
12. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. 2004. Identification of human brain tumour initiating cells. Nature 432:396-401
13. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. 2003. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63:5821-28
14. Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, et al. 2004. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol, 108:49-56
15. Chen PC, Aldape K, Wiencke JK, Kelsey KT, Miike R, et al. 2001. Ethnicity delineates different genetic pathways in malignant glioma. Cancer Res. 61:3949-54
16. Bogler O, Huang H-JS, Cavenee WK. 1995. Loss of wild-type p53 bestows a growth advantage on primary cortical astrocytes and facilitates their in vitro transformation. Cancer Res. 55:2746-51
17. Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T. 2000. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain- specific effects. Nat. Genet. 26:109-13
18. 1NK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 13:1065-72
19. Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A, Collins W. 2000. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res. 60:417-24
20. Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, et al. 1992. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 52:3213-19
21. Hermanson M, Funa K, Koopmann J, Maintz D, Waha A, et al. 1996. Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor a receptor expression in human malignant gliomas. Cancer Res. 56:164-71
22. Ino Y, Silver JS, Blazejewski L, Nishikawa R, Matsutani M, et al. 1999. Common regions of deletion on chromosome 22q12.3-13.1 and 22q13.2 in human astrocytomas appear related to malignancy grade. J. Neuropathol. Exp. Neurol. 58:881-85
23. Schrock E, Blume C, Meffert MC, du Manoir S, Bersch W, et al. 1996. Recurrent gain of chromosome arm 7q in low-grade astrocytic tumors studied by comparative genomic hybridization. Genes Chromosomes Cancer 15:199-205
24. Hirose Y, Aldape KD, Chang S, Lamborn K, Berger MS, Feuerstein BG. 2003. Grade II astrocytomas are subgrouped by chromosome aberrations. Cancer Genet. Cytogenet. 142:1-7
25. Reifenberger G, Louis DN. 2003. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J. Neuropathol. Exp. Neurol. 62:111-26
26. Hartmann C, Johnk L, Kitange G, Wu Y, Ashworth LK, et al. 2002. Transcript map of the 3.7-Mb D19S112-D19S246 candidate tumor suppressor region on the long arm of chromosome 19. Cancer Res. 62:4100-8
27. Smith JS, Tachibana I, Pohl U, Lee HK, Thanarajasingam U, et al. 2000. A transcript map of the chromosome 19 q-arm tumor suppressor region. Genomics 64:44-50
28. Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, et al. 1999. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18:4144-52
29. Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, et al. 2004. Oligodendroglial tumors: refinement of candidate regions on chromosome arm Ip and correlation of 1p/19q status with survival. Brain Pathol. 14:121-30
30. Kraus JA, Koopmann J, Kaskel P, Brandner S, Schramm J, et al. 1995. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J. Neuropathol. Exp. Neurol. 54:91-95
31. Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, et al. 1997. Molecular genetic evidence for subtypes of oligoastrocytomas. J. Neuropathol. Exp. Neurol. 56:1098-104
32. Weiss WA, Israel M, Cobbs C, Holland E, James CD, et al. 2002. Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene 21:7453-63
33. Zlatescu MC, TehraniYazdi AR, Sasaki H, Megyesi JF, Betensky RA, et al. 2001. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res. 61:6713-15
34. Cavenee WK, Furnari FB, Nagane M, Huang H-JS, Newcombe EW, et al. 2000. Diffuse astrocytomas. In Pathology and Genetics of Tumours of the Nervous System, ed. P Kleihues, WK Cavenee, pp. 10-21. Lyon: IARC
35. Uhm JH, Gladson CL, Rao JS. 1999. The role of integrins in the malignant phenotype of gliomas. Front. Biosci. 4:0188-99
36. Rao JS. 2003. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat. Rev. Cancer 3:489-501
37. Natarajan M, Hecker TP, Gladson CL. 2003. FAK signaling in anaplastic astrocytoma and glioblastoma tumors. Cancer J. 9:126-33
38. Okada Y, Hurwitz EE, Esposito JM, Brower MA, Nutt CL, Louis DN. 2003. Selection pressures of TP53 mutation and microenvironmental location influence EGFR gene amplification in human glioblastomas. Cancer Res. 63:413-16
39. Lal A, Glazer CA, Martinsori HM, Friedman HS, Archer GE, et al. 2002. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res. 62:3335-39
40. Penar PL, Khoshyomn S, Bhushan A, Tritton TR. 1997. Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain. Neurosurgery 41:141-51
41. Wang H, Wang HM, Shen WP, Huang H, Hu LM, et al. 2003. Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res. 63:4315-21
42. Megyesi JF, Kachur E, Lee DH, Zlatescu MC, Betensky RA, et al. 2004. Imaging correlates of molecular signatures in oligodendrogliomas. Clin. Cancer Res. 10:4303-6
43. Lamszus K, Kunkel P, Westphal M. 2003. Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir. Suppl. 88:169-77
44. Louis DN, Posner JB, Jacobs T, Kaplan R. 2000. Report of the Brain Tumor Progress Review Group, http://prg.nci.nih.gov/brain/finalreport.html
45. Woher M, Reifenberger J, Blaschke B, Ichimura K, Schmidt EE, et al. 2001. Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p161NK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes. J. Neuropathol. Exp. Neurol. 60:1170-80
46. Weiss WA, Burns MJ, Hackett C, Aldape K, Hill JR, et al. 2003. Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res. 63:1589-95
47. Xiao A, Wu H, Pandolfi PP, Louis DN, Van Dyke T. 2002. Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell 1:157-68
48. Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN. 2001. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am. J. Pathol. 159:359-67
49. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, et al. 1998. Specific chromosomal losses predict chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer Inst. 90:1473-79
50. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, et al. 2001. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin. Cancer Res. 7:839-45
51. Brat DJ, Van Meir EG. 2004. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab. Invest. 84:397-405
52. Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, et al. 2004. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res. 64:920-27
53. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, et al. 1999. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994-98
54. Zagzag D, Hooper A, Friedlander DR, Chan W, Holash J, et al. 1999. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp. Neurol. 159:391-400
55. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, et al. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379:88-91
56. Kinzler KW, Vogelstein B. 1996. Life (and death) in a malignant tumor. Nature 379:19-20
57. Leon SP, Folkerth RD, Black PM. 1996. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 77:362-72
58. Haddad SF, Moore SA, Schelper RL, Goeken JA. 1992. Vascular smooth muscle hyperplasia underlies the formation of glomeruloid vascular structures of glioblastoma multiforme. J. Neuropathol. Exp. Neurol. 51:488-92
59. Plate KH, Breier G, Weich HA, Risau W. 1992. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845-48
60. Brat DJ, Van Meir EG. 2001. Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research. Am. J. Pathol. 158:789-96
61. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, et al. 2000. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J. Clin. Oncol. 18:636-45
62. Chahlavi A, Kanner A, Peereboom D, Staugaitis SM, Elson P, Barnett G. 2003. Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J. Neurooncol. 61:267-73
63. Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, et al. 2004. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J. Clin. Oncol. 22:3133-38
64. Sasaki H, Zlatescu MC, Betensky RA, Johnk LB, Cutone AN, et al. 2002. Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma." J. Neuropathol. Exp. Neurol. 61:58-63
65. van den Bent MJ, Looijenga LHJ, Langenberg K, Dinjens W, Graveland W, et al. 2003. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97:1276-84
66. Bauman GS, Ino Y, Ueki K, Zlatescu MC, Fisher BJ, et al. 2000. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int. J. Radiat. Oncol. Biol. Phys. 48:825-30
67. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN. 1993. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol. 3:19-26
68. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. 1996. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 6:217-23
69. Burger PC, Pearl DK, Aldape K, Yates AJ, Scheithauer BW, et al. 2001. Small cell architecture-a histological equivalent of EGFR amplification in glioblastoma multiforme? J. Neuropathol. Exp. Neurol. 60:1099-104
70. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, et al. 2004. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 64:6892-99
71. Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, et al. 2001. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res. 61:1122-28
72. Meyer-Puttlitz B, Hayashi Y, Waha A, Rollbrocker B, Bostrom J, et al. 1997. Molecular genetic analysis of giant cell glioblastomas. Am. J. Pathol. 151:853-57
73. Kunwar S, Mohapatra G, Bollen A, Lamborn KR, Prados M, Feuerstein BG. 2001. Genetic subgroups of anaplastic astrocytomas correlate with patient age and survival. Cancer Res. 61:7683-88
74. Ino Y, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, et al. 2000. Long patient survival and therapeutic responses in histologically disparate high grade gliomas with chromosome 1p loss. J. Neurosurg. 92:983-90
75. Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, et al. 2002. Impact of genotype and morphology on the prognosis of glioblastoma. J. Neuropathol. Exp. Neurol. 61:321-28
76. Dong S, Nutt CL, Betensky RA, Stemmer-Rachamimov AO, Denko NC, et al. 2006. Histology-based expression profiling yields novel prognostic markers in human glioblastoma. J. Neuropathol. Exp. Neurol. In press